Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients

Leukemia Research

Volumn 34, Issue 10, 2010, Pages 1308-1313

  Pluta, Agnieszka ^a   Wrzesien Kus, Agata ^a   Cebula Obrzut, Barbara ^a   Wolska, Anna ^a   Szmigielska Kaplon, Anna ^a   Czemerska, Magdalena ^a   Pluta, Piotr ^a   Robak, Tadeusz ^a   Smolewski, Piotr ^a   Wierzbowska, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute myeloid leukemia; Apoptosis; Prognosis; Smac DIABLO

Indexed keywords

CYTARABINE; HYDROXYUREA; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; KARYOTYPE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 77955983871     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.11.030     Document Type: Article

References (29)

1. Gudgin E., Huntly B. Acute myeloid leukemia biology and leukemia stem cells. Hematology education: the education program for the annual congress of the European Hematology Association, vol. 3 2009, 17-23.
2. Haferlach T. Molecular genetics pathways as therapeutic targets in acute myeloid leukemia. Hematol Am Soc Hematol Educ Prog 2008, 400-411.
3. Hegde R., Srinivasula S.M., Zhang Z., Wassell R., Mukattash R., Cilenti L., et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002, 277:432-438.
4. Martins L.M., Iaccarino I., Tenev T., Gschmeissner S., Totty N.F., Lemoine N.R., et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 2002, 277:439-444.
5. Verhagen A.M., Silke J., Ekert P.G., Pakusch M., Kaufmann H., Connolly L.M., et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem 2002, 277:445-454.
6. Leaman D.W., Chawla-Sarkar M., Vyas K., Reheman M., Tamai K., Toji S., et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 2002, 277:28504-28511.
7. Yan N., Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol 2005, 21:35-56.
8. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
9. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
10. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
11. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
12. Fu J., Jin Y., Arend L.J. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J Biol Chem 2003, 278:52660-52672.
13. Jia L., Patwari Y., Kelsey S.M., Srinivasula S.M., Agrawal S.G., Alnemri E.S., et al. Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene 2003, 22:1589-1599.
14. Wrzesień-Kuś A., Smolewski P., Sobczak-Pluta A., Wierzbowska A., Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 2004, 9:705-715.
15. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
16. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 30:937-951.
17. Holowiecki J., Grosicki S., Kyrcz-Krzemien, Kuliczkowski K., Skotnicki A., Hellmann A., et al. Addition of cladribine to the standard daunorubicine-cytarabine (DA 3+7) remission induction protocol (DAC) contrary to adjunct of fludarabine (DAF) improves the overall survival in untreated adults with acute myeloid leukemia aged up to 60Y: a multicenter, randomized, phase III PALG AML 1/2004 DAF/DAC/DA study in 673 patients. Blood 2008, 112:133. [Abstract].
18. Cheson B.D., Bennett J.M., Kopecky K.J., Büchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649. [Erratum in: J Clin Oncol 2004;22:576].
19. Yoo N.J., Kim H.S., Kim S.Y., Park W.S., Park C.H., Jeon H.M., et al. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. APMIS 2003, 111:382-388.
20. Endo K., Kohnoe S., Watanabe A., Tashiro H., Sakata H., Morita M., et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep 2009, 21:351-355.
21. Yan Y., Mahotka C., Heikaus S., Shibata T., Wethkamp N., Liebmann J., et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer 2004, 4(91):1349-1357.
22. Bao S.T., Gui S.Q., Lin M.S. Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006, 5:580-583.
23. Anguiano-Hernandez Y.M., Chartier A., Huerta S. Smac/DIABLO and colon cancer. Anticancer Agents Med Chem 2007, 7:467-473.
24. Ren Y., Akyurek N., Schlette E., Rassidakis G.Z., Medeiros L.J. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. Hum Pathol 2006, 37:1407-1413.
25. Kempkensteffen C., Hinz S., Christoph F., Krause H., Magheli A., Schrader M., et al. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol 2008, 134:543-550.
26. Mizutani Y., Nakanishi H., Yamamoto K., Li Y.N., Matsubara H., Mikami K., et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 2005, 23:448-454.
27. Heerema-McKenney A., Arber D.A. Acute myeloid leukemia. Hematol Oncol Clin N Am 2009, 23:633-654.
28. Mrózek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008, 35:365-377.
29. Klepin H.D., Balducci L. Acute myelogenous leukemia in older adults. Oncologist 2009, 14:222-232.